149 related articles for article (PubMed ID: 9706471)
1. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro.
Köpf-Maier P
In Vivo; 1998; 12(3):275-88. PubMed ID: 9706471
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
3. Treosulfan in the treatment of metastatic renal cell carcinoma.
Rigos D; Wechsel HW; Bichler KH
Anticancer Res; 1999; 19(2C):1549-52. PubMed ID: 10365143
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
Lanvers-Kaminsky C; Bremer A; Dirksen U; Jürgens H; Boos J
Anticancer Drugs; 2006 Jul; 17(6):657-62. PubMed ID: 16917211
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of treosulfan against human breast carcinomas.
Köpf-Maier P; Sass G
Cancer Chemother Pharmacol; 1992; 31(2):103-10. PubMed ID: 1451231
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of treosulfan in human lung carcinomas.
Köpf-Maier P; Sass G
Cancer Chemother Pharmacol; 1996; 37(3):211-21. PubMed ID: 8529280
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
10. Screening for and identification of novel agents directed at renal cell carcinoma.
Mertins SD; Myers TG; Hollingshead M; Dykes D; Bodde E; Tsai P; Jefferis CA; Gupta R; Linehan WM; Alley M; Bates SE
Clin Cancer Res; 2001 Mar; 7(3):620-33. PubMed ID: 11297258
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
13. Myeloablative and immunosuppressive properties of treosulfan in mice.
Sjöö F; Hassan Z; Abedi-Valugerdi M; Griskevicius L; Nilsson C; Remberger M; Aschan J; Concha H; Gaughan U; Hassan M
Exp Hematol; 2006 Jan; 34(1):115-21. PubMed ID: 16413398
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of treosulfan on prostate cancer cell lines.
Feyerabend S; Feil G; Krug J; Kassen A; Stenzl A
Anticancer Res; 2007; 27(4B):2403-8. PubMed ID: 17695531
[TBL] [Abstract][Full Text] [Related]
15. Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL).
Fichtner I; Becker M; Baumgart J
Eur J Cancer; 2003 Apr; 39(6):801-7. PubMed ID: 12651206
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.
Loaiza-Pérez AI; Kenney S; Boswell J; Hollingshead M; Hose C; Linehan WM; Worrell R; Rubinstein L; Sausville EA; Vistica DT
J Urol; 2004 Apr; 171(4):1688-97. PubMed ID: 15017268
[TBL] [Abstract][Full Text] [Related]
19. DNA alkylation and interstrand cross-linking by treosulfan.
Hartley JA; O'Hare CC; Baumgart J
Br J Cancer; 1999 Jan; 79(2):264-6. PubMed ID: 9888467
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]